LC
RARE icon

Lindbrook Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Lindbrook Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.58K Buy
154
+75
+95% +$3.12K ﹤0.01% 1907
2024
Q4 		$3.32K Sell
79
-78
-50% -$3.87K ﹤0.01% 2138
2024
Q3 		$8.72K Buy
157
+78
+99% +$3.97K ﹤0.01% 1745
2024
Q2 		$3.25K Sell
79
-38
-32% -$1.62K ﹤0.01% 2184
2024
Q1 		$5.46K Buy
117
+18
+18% +$849 ﹤0.01% 1858
2023
Q4 		$4.73K Buy
99
+14
+16% +$543 ﹤0.01% 1916
2023
Q3 		$3.03K Sell
85
-135
-61% -$5.35K ﹤0.01% 1979
2023
Q2 		$10.1K Buy
220
+28
+15% +$1.3K ﹤0.01% 1459
2023
Q1 		$7.7K Sell
192
-248
-56% -$10.6K ﹤0.01% 1623
2022
Q4 		$20.4K Buy
440
+326
+286% +$12.8K ﹤0.01% 1053
2022
Q3 		$5K Buy
+114
New +$5.86K ﹤0.01% 1686
2022
Q2 		– Sell
-28
Closed -$2K – 2715
2022
Q1 		$2K Buy
28
+4
+17% +$278 ﹤0.01% 2058
2021
Q4 		$2K Buy
+24
New +$1.95K ﹤0.01% 1813
2021
Q2 		– Sell
-7
Closed -$1K – 1992
2021
Q1 		$1K Buy
+7
New +$953 ﹤0.01% 1774
2020
Q1 		– Sell
-17
Closed -$1K – 1831
2019
Q4 		$1K Sell
17
-70
-80% -$2.89K ﹤0.01% 1427
2019
Q3 		$4K Buy
87
+24
+38% +$1.3K ﹤0.01% 1120
2019
Q2 		$4K Hold
63
– – ﹤0.01% 1120
2019
Q1 		$4K Hold
63
– – ﹤0.01% 1135
2018
Q4 		$2K Buy
+63
New +$3.44K ﹤0.01% 1201

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Lindbrook Capital's RARE Position: Q1 2025 in Review

Lindbrook Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 95% in Q1 2025, buying an estimated $3.12K and bringing the position to 154 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1907.

Lindbrook Capital first reported a position in RARE in Q4 2018 and has held it in 19 quarters since. The position peaked at $20.4K in Q4 2022. 300 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • Lindbrook Capital held 154 shares of Ultragenyx Pharmaceutical worth $5.58K as of Q1 2025.
  • Lindbrook Capital bought 75 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $3.12K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1907 holding.
  • Lindbrook Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and has held it in 19 quarters since.
  • Lindbrook Capital's Ultragenyx Pharmaceutical position peaked at $20.4K in Q4 2022.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.